3SQ3 Flashcards
which is a CB1 receptor agonist?
a. opioids
b. cannabinoids
c. LSD
d. mescaline
b. cannabinoids
drug used for treatment of alcoholism and opioid addiction
a. naloxone
b. naltrexone
c. methadone
d. buprenorphine
b. naltrexone
partial agonist of nicotinic acetylcholine receptor used smoking cessation
a. acamprosate
b. bupropion
c. naloxone
d. varenicline
d. varenicline
endogenous cannabinoids
a. 2-arachidonoyl glycerol
b. anandamide
c. both
d. neither
c. both
non-selective opioid antagonist and partial agonist used for treating addiction
a. baclofen
b. methadone
c. naltrexone
d. rimonabant
c. naltrexone
a recalcitrant, chronic, and stubbornly relapsing disease that is very difficult to treat
a. addiction
b. withdrawal
c. relapse
d. dependence
a. addiction
compulsive, relapsing drug use despite negative consequences, at times triggered by cravings that occur in response to contextual cues
a. addiction
b. withdrawal
c. relapse
d. dependence
a. addiction
antidote for opioid overdose
a. flumazenil
b. naloxone
c. methadone
d. morphine
b. naloxone
antidote for benzodiazepine toxicity
a. flumazenil
b. naloxone
c. methadone
d. morphine
b. naloxone
clinically used as cough suppressant
a. morphine
b. nalbuphine
c. dextromethorphan
d. naloxone
c. dextromethorphan
Kappa agonist and mu agonist
a. buprenorphine
b. nalbuphine
c. tapentadol
d. tramadol
b. nalbuphine
this activates the melanin receptors in suprachiasmatic nuclei
a. ramelteon
b. suvorexant
c. buspirone
d. flumazenil
a. ramelteon
thiopental
a. requires a loading dose
b. partial agonist at 5-HT
c. induction agent for anesthesia
d. binds more selectively to Bz receptors
c. induction agent for anesthesia
phenobarbital
a. requires a loading dose
b. partial agonist at 5-HT
c. induction agent for anesthesia
d. binds more selectively to Bz receptors
a. requires a loading dose
buspirone
a. requires a loading dose
b. partial agonist at 5-HT
c. induction agent for anesthesia
d. binds more selectively to Bz receptors
b. partial agonist at 5-HT
zaleplon
a. requires a loading dose
b. partial agonist at 5-HT
c. induction agent for anesthesia
d. binds more selectively to Bz receptors
d. binds more selectively to Bz receptors
facilitates GABA-mediated chloride ion channel opening frequency
a. barbiturate
b. benzodiazepene
c. both
d. neither
a. barbiturate
binds to GABA-A receptors
a. barbiturate
b. benzodiazepene
c. both
d. neither
a. barbiturate
oxymorphone
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
b. strong agonist
naltrexone
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
d. antagonist
buprenorphine
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
a. mixed agonist-antagonist
steeper dose response curve
a. barbiturate
b. benzodiazepene
c. both
d. neither
a. barbiturate
morphine
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
b. strong agonist
codeine
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
c. moderate agonist
nalmefene
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
d. antagonist
propoxyphene
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
e. weak agonist
pentazocine
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
a. mixed agonist-antagonist
analgesic mechanism
a. kappa receptor
b. mu receptor
c. delta receptor
d. all of the above
d. all of the above
respiratory depressant action
a. kappa receptor
b. mu receptor
c. delta receptor
d. all of the above
b. mu receptor
sedative actions
a. kappa receptor
b. mu receptor
c. delta receptor
d. all of the above
b. mu receptor
benzodiazepine
a. acetylcholine receptor agonist
b. NMDA receptor agonist
c. Dopamine transporter blocker
d. reverses serotonin transport
e. GABA receptor modulator
e. GABA receptor modulator
cocaine
a. acetylcholine receptor agonist
b. NMDA receptor agonist
c. Dopamine transporter blocker
d. reverses serotonin transport
e. GABA receptor modulator
c. Dopamine transporter blocker
ecstasy
a. acetylcholine receptor agonist
b. NMDA receptor agonist
c. Dopamine transporter blocker
d. reverses serotonin transport
e. GABA receptor modulator
d. reverses serotonin transport
nicotine
a. acetylcholine receptor agonist
b. NMDA receptor agonist
c. Dopamine transporter blocker
d. reverses serotonin transport
e. GABA receptor modulator
a. acetylcholine receptor agonist
phenycyclidine
a. acetylcholine receptor agonist
b. NMDA receptor agonist
c. Dopamine transporter blocker
d. reverses serotonin transport
e. GABA receptor modulator
b. NMDA receptor agonist
clinically used for moderate pain
a. morphine
b. nalbuphine
c. dextromethorphan
d. naloxone
b. nalbuphine
this binds to GABA A receptors
a. nicotine
b. alcohol
c. benzodiazepines
d. phencyclidine
c. benzodiazepines
this pyrazolopyrimidine is used for sleep disorder
a. benzodiazepine
b. eszopicione
c. zolpidem
d. zaleplon
d. zaleplon
exogenous cannabinoids
a. THC
b. CBD
c. both
d. neither
c. both
nonselective opioid antagonist and partial agonist used for treating addiction
a. baclofen
b. methadone
c. naltrexone
d. rimonabant
c. naltrexone
in substance abuse the old term physical dependence is now known as
a. addiction
b. withdrawal
c. relapse
d. dependence
d. dependence
which is a serotonin receptor partial agonist
a. opioids
b. cannabinoids
c. LSD
d. mescaline
c. LSD
THC analog for now used for treatment of chemotherapy-induced emesis
a. dronabinol
b. nabilone
c. methadone
d. rimonabant
b. nabilone
methadone
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
b. strong agonist
oxycodone
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
c. moderate agonist or b. strong agonist
nalbuphine
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
c. moderate agonist
naloxone
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
a. mixed agonist-antagonist
tramadol
a. mixed agonist-antagonist
b. strong agonist
c. moderate agonist
d. antagonist
e. weak agonist
e. weak agonist
cocaine
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
c. bind to transporters of biogenic amines
ecstasy
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
c. bind to transporters of biogenic amines
nicotine
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
b. bind to ionotropic receptors and ion channels
phencyclidine
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
b. bind to ionotropic receptors and ion channels
affinity to mu receptors
a. endorphins > enkephalins
b. endorphins < enkephalins
c. endorphins = enkephalins
a. endorphins > enkephalins
affinity to kappa receptors
a. endorphins > enkephalins
b. endorphins < enkephalins
c. endorphins = enkephalins
c. endorphins = enkephalins
affinity to delta receptors
a. endorphins > enkephalins
b. endorphins < enkephalins
c. endorphins = enkephalins
b. endorphins < enkephalins
alcohol
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
b. bind to ionotropic receptors and ion channels
LSD
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
a. activate g protein-coupled receptors
amphetamine
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
c. bind to transporters of biogenic amines
GHB
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
a. activate g protein-coupled receptors
cannabinoids
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
a. activate g protein-coupled receptors
ketamine
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
b. bind to ionotropic receptors and ion channels
mescaline
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
a. activate g protein-coupled receptors
buspirone
a. activates the melanin receptors in suprachiasmatic nuclei
b. partial serotonin agonist is usec for generalized anxiety states
c. blocks orexins that promote sleep onset and duration
d. blocks its GABA-A receptor binding site
b. partial serotonin agonist is usec for generalized anxiety states
tasimelteon
a. Activates the melanin receptors in suprachiasmatic nuclei
b. partial serotonin agonist is usec for generalized anxiety states
c. blocks orexins that promote sleep onset and duration
d. blocks its GABA-A receptor binding site
a. Activates the melanin receptors in suprachiasmatic nuclei
ramelteon
a. Activates the melanin receptors in suprachiasmatic nuclei
b. partial serotonin agonist is usec for generalized anxiety states
c. blocks orexins that promote sleep onset and duration
d. blocks its GABA-A receptor binding site
a. Activates the melanin receptors in suprachiasmatic nuclei
suvorexant
a. Activates the melanin receptors in suprachiasmatic nuclei
b. partial serotonin agonist is usec for generalized anxiety states
c. blocks orexins that promote sleep onset and duration
d. blocks its GABA-A receptor binding site
c. blocks orexins that promote sleep onset and duration
opioid
a. activate g protein-coupled receptors
b. bind to ionotropic receptors and ion channels
c. bind to transporters of biogenic amines
d. all of the given
e. none of the given
a. activate g protein-coupled receptors
crosses the placental barrier
a. barbiturate
b. benzodiazepine
c. both
d. neither
c. both
has high affinity to GABA-B receptors
a. barbiturate
b. benzodiazepine
c. both
d. neither
d. neither
hepatic drug-metabolizing enzyme inducer
a. barbiturate
b. benzodiazepine
c. both
d. neither
a. barbiturate *
clinically used for severe pain
a. morphine
b. nalbuphine
c. dextromethorphan
d. naloxone
a. morphine
This imidazopyridine is used for sleep disorder
a. benzodiazepine
b. eszopiclone
c. zolpidem
d. zalepion
a. benzodiazepine
blocks central muscarinic receptors
a. amphetamine
b. GHB
c. Ketamine
d. Psilocybin
e. Scopolamine
e. Scopolamine ***
blocks DA uptake
a. amphetamine
b. GHB
c. Ketamine
d. Psilocybin
e. Scopolamine
a. amphetamine ***
disinhibition of DA neurons
a. amphetamine
b. GHB
c. Ketamine
d. Psilocybin
e. Scopolamine
b. GHB ***
NMDA receptor antagonist
a. amphetamine
b. GHB
c. Ketamine
d. Psilocybin
e. Scopolamine
c. Ketamine ***
nonaddictive
a. amphetamine
b. GHB
c. Ketamine
d. Psilocybin
e. Scopolamine
c. Ketamine or d. Psilocybin ***
Mechanism of Action: Nicotine
Acetylcholine receptors
Has additive effects with ethanol
a. Benzodiazepine
b. Barbiturate
c. both
d. neither
c. both
antagonized by flumazenil
Benzodiazepine
exerts a calming effect
a. sedative
b. hypnotic
c. both
d. neither
d. neither ***
Adverse effect/s with acute use of opioid analagesics
Urinary retention
Adverse effect/s with acute use of opioid analagesics
respiratory depression
Clinically used to treat pulmonary edema
morphine
Function includes sedation
a. mu receptor
b. delta receptor
c. both
d. neither
a. mu receptor
Function includes modulation of hormones
a. mu receptor
b. delta receptor
c. both
d. neither
c. both
Quantitative Comparison of Sedative Hypnotic Dose for CNS effect:
a. Anesthesia > Coma
b. Anesthesia < Coma
c. Anesthesia = Coma
b. Anesthesia < Coma
Delta-9-tetra-hydrocannabinol
Marijuana
Most addictive drug in the group
opioids
Synthetic analog of THC cannabinoid agonist
dronabinol
Drugs of abuse that acts on G protein-coupled receptors
